Invivyd, Inc (IVVD)

Invivyd, Inc (IVVD) ​ ​I have been extremely high on Invivyd, Inc (IVVD) ​IVVD setup ahead of Phase 3 VYD2311 readout late Q3 I've been tracking Invivyd (IVVD) heading into the end of the month, and the risk/reward profile looks pretty compelling ahead of their Phase 3 data drop. They're expecting top-line results for their next-gen COVID antibody candidate, VYD2311, across two pivotal trials: DECLARATION for efficacy and LIBERTY, which directly compares its side-effect profile against standard mRNA vaccines. ​The main reason this is on my radar is that management actually upsized the DECLARATION trial mid-stream by about 500 patients. Mid-stage trial expansions usually mean leadership wants to guarantee maximum statistical power for clear positive results, which signals high confidence in their event accumulation data. On top of that, the LIBERTY study puts VYD2311 head-to-head with mRNA shots. If the data proves it offers strong protection without giving people the usual 2 to 3 days of heavy side effects like fever and body aches, it opens up a massive commercial market of people who actively avoid standard vaccines. ​What makes the setup even cleaner is that IVVD isn't just a zero-revenue story play, they're already generating revenue from their first-gen antibody PEMGARDA, giving them a real commercial footprint. Board Chair Marc Elia also stepped into the CEO role right as they hit the home stretch for this readout, which usually indicates leadership is gearing up for commercial execution or strategic positioning. If the Phase 3 data comes back clean, it immediately positions VYD2311 for a full BLA filing. Given the low valuation and micro-cap dynamics heading into data, a positive result could trigger a rapid re-rate toward analyst price targets.